Abstract: Novel antifibrinolytically active compounds of the formula ##STR1## and therapeutically acceptable salt thereof, whereinR.sup.1 is selected from the group consisting of(a) alkyl groups containing 1-4 carbon atoms,(b) alkoxy groups containing 1-4 carbon atoms, ##STR2## R.sup.2 is selected from the group consisting of (a) H,(b) alkyl groups containing 1-4 carbon atoms,(c) --COOR.sup.3, wherein R.sup.3 is an alkyl group containing 1-4 carbon atoms,(d) --CONR.sup.4 R.sup.5, wherein R.sup.4 and R.sup.5 are the same or different alkyl groups containing 1-3 carbon atoms;or wherein R.sup.1 and R.sup.

Abstract: New compounds of the general formula I ##STR1## wherein R.sup.1 and R.sup.2 each independently represent an alkyl group containing 1 to 4 carbon atoms, or an alkoxy group containing 1 to 3 carbon atoms, or halogen, R.sup.3 represents hydrogen, halogen, an alkyl group containing 1 to 4 carbon atoms, an alkoxy group containing 1 to 3 carbon atoms, an amino group or a nitro group, A represents ##STR2## which is bonded to the benzene ring by its sulphur or nitrogen atom and in which R.sup.4 is hydrogen or an alkyl group containing 1 to 4 carbon atoms; together with salts thereof with physiologically acceptable acids and, when R.sup.4 is hydrogen, with physiologically acceptable bases are described. The compounds are of use in inhibiting thrombosis formation, in treating thrombosis and in fibronolytic therapy. Various methods of producing the new compounds are described involving the building up of the --A--CH.sub.2 --CH.sub.2 --S--CH.sub.2 CH.sub.2 NH.sub.

Abstract: The blood coagulation factors I (fibrinogen) and VIII (antihemophilia factor, abbreviated AHF) are isolated in high yields from animal tissue materials such as blood or blood products (e.g. plasma) or plasma fractions by a procedure involving the essential step of adsorption (as in affinity chromatography) of at least one of these factors, in a liquid system, onto a water-insoluble gel matrix primarily composed of a cross-linked sulfated or sulfonated, gel-forming carbohydrate such as cross-linked dextran sulfate-agarose, cross-linked dextran sulfate-dextran, cross-linked heparin-agarose and other such gel matrix-providing substances.

Abstract: Disclosed and claimed is the preparation of the 4-aminomethyl-cyclohexane carboxylic acid isomer assaying at least about 90% antifibrinolytically active material from specific para-disubstituted cyclohexane starting material. For example, in 4-aminomethyl-cyclohexane methanol such as its isomer melting at 118.degree. C. in a series of steps its methanol group is converted to carboxyl. More specifically its amino group is blocked by reaction with benzoyl halide and the methanol group then oxidized to carboxyl, and the benzoyl group removed to yield the end product isomer.1-4-dimethyl-cyclohexane dicarboxylate melting at 69.degree.-71.degree. C., another such cyclohexane starting material, is hydrolyzed to its mono-ester which with thionyl halide is converted to the halide of the half-ester, which latter reacted with ammonia gives the corresponding ester amide.